InsiderClue
← All stocks

Tango Therapeutics, Inc.

TNGX Net selling
CIK 0001819133 #1540 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$15.68M
$997.97K on a plan · $5.10M straight out of an exercise
Sold at will
$9.58M
8 of 22 sales
Net
−$15.68M
−$9.58M against sales at will

By person

15 insiders · 22 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Third Rock Ventures IV, L.P. entity
10% owner
—
$8.86M (2)
−$8.86M
13,386,574
7.94%
$299.42M
−20.6%
Crystal Adam
President, R&D
—
$6.33M (16) scheduled
−$6.33M
115,743
0.0686%
$2.59M
−5.6%
Weber Barbara
Director, Executive Chair
—
$374.29K (2)
−$374.29K
1,629,254
0.9663%
$36.44M
+6.1%
Beckman Daniella
Chief Financial Officer
—
$126.53K (2)
−$126.53K
184,297
0.1093%
$4.12M
+39.2%
EcoR1 Capital, LLC entity
10% owner
—
—
—
10,630,736
6.30%
$237.78M
−20.3%
Boxer Capital Management, LLC entity
See remarks
—
—
—
10,301,284
6.11%
$230.41M
−30.8%
Peters Malte
President & CEO
—
—
—
367,500
0.2180%
$8.22M
+3,167%
Barry Douglas
General Counsel
—
—
—
66,014
0.0392%
$1.48M
+50.1%
Rothenberg Mace
Director
—
—
—
41,500
0.0246%
$928.23K
+268.9%
Gall Matthew
Chief Financial Officer
—
—
—
40,000
0.0237%
$894.68K
—
Ketchum John B
Director
—
—
—
24,937
0.0148%
$557.77K
+69.8%
Lee Sung
Director
—
—
—
22,870
0.0136%
$511.53K
—
Borisy Alexis
Director
—
—
—
17,500
0.0104%
$391.42K
+55.6%
Calhoun Lesley Ann
Director
—
—
—
16,500
0.0098%
$369.06K
+164.0%
Azelby Robert
Director
—
—
—
5,740
0.0034%
$128.39K
—

Individual transactions

12
Insider
Date
Role
Action
Shares
Price
Amount
Crystal Adam
1 Sep 2026
President, R&D
Sold after exercise
27,000
$22.37
$603.91K
Crystal Adam
3 Aug 2026
President, R&D
Sold after exercise
21,733
$27.35
$594.42K
Crystal Adam
3 Aug 2026
President, R&D
Sold after exercise
5,267
$26.79
$141.10K
Crystal Adam
1 Jul 2026
President, R&D
Sold after exercise
7,371
$30.25
$222.95K
Crystal Adam
1 Jul 2026
President, R&D
Sold after exercise
19,629
$29.34
$575.96K
Crystal Adam
1 Jun 2026
President, R&D
Sold after exercise
20,860
$23.06
$480.94K
Crystal Adam
1 Jun 2026
President, R&D
Sold after exercise
6,140
$22.25
$136.63K
Crystal Adam
1 May 2026
President, R&D
Sold after exercise
1,100
$22.00
$24.20K
Crystal Adam
1 May 2026
President, R&D
Sold after exercise
25,900
$21.19
$548.90K
Crystal Adam
15 Apr 2026
President, R&D
Sold after exercise
38,460
$25.00
$961.50K
Crystal Adam
1 Apr 2026
President, R&D
Sold after exercise
27,000
$21.20
$572.48K
Crystal Adam
25 Mar 2026
President, R&D
Sold after exercise
12,000
$20.11
$241.32K
Show all 22 transactions →

What was left out

Form 4 filings counted 26
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 12
Sales at will 8
Transactions with no price 0
Shares from compensation/vesting 772,382
History held since 10 Sep 2020